Immunological Drug Testing: Screening and Forensic Interpretation

Every immunoassay drug test exploits the same fundamental property: an antibody raised against a drug molecule, or a hapten-protein conjugate of that molecule, will bind the drug with high affinity and, to a lesser extent, with structurally related compounds. The drug molecule itself is too small to be immunogenic, so animals used to generate antibodies for diagnostic use are immunised with a conjugate of the drug hapten linked to a carrier protein such as bovine serum albumin or keyhole limpet haemocyanin. The resulting polyclonal or monoclonal antibody recognises the drug's structural epitope, the particular arrangement of atoms that fits the antibody's binding site.

In a competitive immunoassay, labelled drug (the tracer) and unlabelled drug from the specimen compete for a fixed, limited number of antibody binding sites. The higher the concentration of unlabelled drug in the specimen, the less tracer is captured by antibody, and the stronger the signal from free tracer. The relationship between signal and concentration is an inverse sigmoid curve, calibrated against standards of known concentration. The precision of the assay depends on the affinity constant of the antibody: high-affinity antibodies allow detection at lower concentrations but are not necessarily more specific.

Specificity is distinct from affinity. An antibody can bind its primary target with nanomolar affinity while also binding a metabolite or a structurally related drug at micromolar affinity. Whether that lower-affinity binding causes a problem in practice depends on whether the cross-reactant is likely to be present in the specimen at concentrations high enough to produce a signal at or above the cut-off. This is why immunoassay manufacturers publish cross-reactivity tables: they report the concentration of each tested compound required to produce a signal equivalent to the cut-off concentration of the primary analyte. Those tables are essential reading for anyone interpreting immunoassay results in a forensic setting.

EMIT was developed by Syva Company and introduced in 1972. It was the first homogeneous immunoassay to be automated on clinical chemistry analysers. Homogeneous means the assay requires no physical separation of bound from free tracer: the signal difference between antibody-bound and free enzyme-labelled conjugate is detectable in the same solution. This property makes EMIT amenable to automation on high-throughput platforms already present in hospital clinical chemistry laboratories, which is why EMIT-based drug screens became the standard in hospital emergency toxicology and workplace testing programmes.

In EMIT, the tracer is the target drug conjugated to glucose-6-phosphate dehydrogenase (G6PDH). The reaction measures conversion of NAD to NADH, detected as absorbance increase at 340 nm. When antibody binds the G6PDH-drug conjugate, the enzyme's active site is sterically blocked and activity drops. When sample drug outcompetes the conjugate for antibody binding, the G6PDH conjugate remains free and active, and absorbance rises. The net absorbance change over a defined time window is compared to a calibration curve to assign a qualitative positive or negative result relative to the cut-off.

CEDIA was developed by Boehringer Mannheim (now Roche Diagnostics) and introduced in the early 1990s. It uses two fragments of the bacterial enzyme beta-galactosidase: an enzyme donor (ED) fragment and an enzyme acceptor (EA) fragment. Neither fragment alone is enzymatically active; they must associate to form an active tetramer. Drug is conjugated to the small ED fragment. When ED-drug is free, it associates with EA and enzyme activity is measurable. When antibody binds ED-drug, it prevents the ED-EA association, reducing enzyme activity. Sample drug competes with ED-drug for antibody binding, freeing ED-drug to associate with EA and increase signal. CEDIA offers slightly lower background interference than EMIT in some matrices.

Both EMIT and CEDIA are implemented as reagent kits on automated chemistry analysers such as the Siemens Viva-E, Abbott Architect, and Beckman Coulter AU series. A single analyser running a full drug panel (opiates, amphetamines, cannabinoids, cocaine metabolite, benzodiazepines, barbiturates, phencyclidine, ethanol) can process hundreds of specimens per hour. In a large forensic toxicology laboratory handling post-mortem referrals and workplace samples, this throughput makes immunoassay screening the only practical first-tier approach before selective chromatographic confirmation.

Lateral-flow immunoassays are point-of-care devices designed for use outside the laboratory. They are single-use strips enclosed in a plastic cassette. The nitrocellulose membrane carries two lines: a test line (T) coated with drug-protein conjugate and a control line (C) coated with anti-species antibody. Colloidal gold-labelled antibody is stored in a conjugate pad at one end of the strip. When urine is added, it rehydrates the conjugate pad and migrates toward the other end of the strip by capillary action.

The result interpretation is counterintuitive. If the urine contains no drug above the cut-off, the labelled antibody migrates freely and is captured at the test line (drug-protein conjugate binds the antibody), producing a visible coloured band. A second band forms at the control line from excess labelled antibody. Two lines: negative result. If the urine contains drug at or above the cut-off, the drug saturates the labelled antibody during migration. When the complex reaches the test line, no antibody sites remain available to bind the immobilised drug-protein conjugate, so no test line band forms. Only the control line appears. One line (control only): positive result. A strip with no control line is invalid regardless of test line appearance.

Lateral-flow strips are used in roadside drug testing programmes across numerous jurisdictions. The Dräger DrugTest 5000 and Alere DDS2 are oral-fluid devices deployed by police in the United Kingdom under the Drug Driving Regulations 2014, Australia under state-level transport legislation, and several European Union member states under their national road safety laws. Indian state motor vehicle enforcement units use urine-based lateral-flow strips at checkpoints, with positive results triggering mandatory referral for blood collection and laboratory analysis. In all of these programmes, the strip result is a screening tool: a positive screen initiates the confirmation workflow, it does not itself constitute evidence of impairment or a specific blood drug concentration.

Cross-reactivity is the principal analytical limitation of immunoassay drug testing. It arises because an antibody recognises a molecular epitope shared, to varying degrees, by structurally related compounds. The wider the structural family, the more compounds that can cross-react. Drug class assays are intentionally designed with some degree of cross-reactivity to ensure that both parent drug and major metabolites are detected: an opiate assay must detect morphine, codeine, 6-monoacetylmorphine, and dihydrocodeine, not just morphine alone. But the same broad recognition that captures these legitimate analytes also captures unintended compounds.

Common forensically relevant cross-reactivities include: poppy seed consumption producing urine morphine and codeine concentrations that exceed immunoassay cut-offs; the antibiotic rifampicin triggering opiate screens; pseudoephedrine and ephedrine (present in over-the-counter cold medicines) triggering amphetamine screens; the antihistamine doxylamine triggering methamphetamine screens at high doses; the proton pump inhibitor pantoprazole triggering tetrahydrocannabinol (THC) screens on some assay platforms; the nonsteroidal anti-inflammatory drug ibuprofen triggering cannabinoid screens on older EMIT formulations. The forensic significance of each cross-reactant depends on the concentration typically achievable in the matrix being tested.

False negatives are less discussed but also occur. If a drug or its metabolite is present at a concentration below the cut-off, the immunoassay will not flag it. In post-mortem specimens, extensive post-mortem redistribution may concentrate drugs above the cut-off when the ante-mortem blood level was therapeutic, but the reverse is also possible: drugs that are highly protein-bound or sequestered in tissues may be present in low-free-drug concentrations in blood while being present at high concentrations in liver or vitreous humour, which the immunoassay screen on peripheral blood would miss.

In post-mortem toxicology, immunoassay screening is applied to peripheral blood, urine (when recoverable), bile, and vitreous humour. The specimen choice matters: vitreous humour is the matrix least affected by post-mortem redistribution and microbial contamination, making it the preferred specimen for initial screening when decomposition is advanced. Peripheral blood from an arm or leg vein reflects ante-mortem distribution more accurately than central (cardiac) blood. The immunoassay screen on post-mortem specimens is a triage tool that directs the toxicologist toward the analyte classes to pursue with chromatographic methods; it does not determine the cause of death or the concentration responsible for impairment.

Workplace drug testing programmes in the United States operate under SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs. The guidelines specify five mandatory drug panels (marijuana metabolites, cocaine metabolites, amphetamines, opioids, and phencyclidine), initial test cut-off concentrations, confirmation test cut-off concentrations, and the requirement for GC-MS or LC-MS/MS confirmation. A certified medical review officer (MRO) reviews all positive confirmation results before reporting to the employer, specifically to evaluate whether a legitimate medical explanation exists. Similar frameworks exist in the United Kingdom under the Faculty of Occupational Medicine guidelines, in Australia under AS/NZS 4308:2008, and in India under various industrial safety regulations that reference international standards.

Drug-facilitated sexual assault (DFSA) casework presents distinct immunoassay challenges. The drugs used in DFSA cases, gamma-hydroxybutyrate (GHB), flunitrazepam, ketamine, and others, may be present at low concentrations and may be eliminated within hours of ingestion. Standard hospital urine drug screens are calibrated for therapeutic and abuse concentrations of common drugs; they may not detect DFSA-relevant compounds at the concentrations present in a delayed-collection specimen. Specific immunoassay reagents for GHB and flunitrazepam exist and are used in specialist laboratories, but collection timing is critical. Most DFSA guidelines recommend blood and urine collection within 72 hours, with earlier collection strongly preferred.

Hair immunoassay screening has become a routine first step in hair drug testing, particularly for chronic drug exposure in child protection proceedings and long-term employment screening. ELISA-based hair screen assays are offered by specialist laboratories. Cross-reactivity concerns in hair are complicated by the possibility of external drug contamination deposited on the hair surface rather than incorporated into the hair shaft from blood, a distinction that chromatographic methods can sometimes, but not always, resolve by comparing internal to external drug distribution.

Gas chromatography-mass spectrometry (GC-MS) remains the reference method for confirmatory drug testing. The specimen extract is separated on a capillary column by boiling point and polarity, then each eluting compound is fragmented by electron ionisation and the fragment ion mass spectrum is recorded. A compound is confirmed when its retention time and mass spectrum match those of an authenticated reference standard within defined tolerances. GC-MS can quantify the confirmed compound at concentrations typically in the range of 1 to 50 ng/mL depending on the drug and the extraction procedure used.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has largely supplemented GC-MS for confirmation of polar, thermolabile, or high-molecular-weight compounds such as benzodiazepines, glucuronide metabolites, and synthetic cannabinoids that require derivatisation before GC-MS analysis. LC-MS/MS operates in multiple reaction monitoring (MRM) mode, selecting a precursor ion and two product ions for each analyte. The ratio of the two product ions must match the reference standard within accepted limits. LC-MS/MS offers lower limits of detection for many compounds and is the method of choice in post-mortem laboratories needing to screen for a broad range of new psychoactive substances.

The confirmation process also provides quantification, which the immunoassay screen does not. In a post-mortem context, quantification of blood drug concentrations allows comparison to published therapeutic, toxic, and lethal reference ranges, supporting the toxicologist's opinion on whether the drug concentration could have contributed to death. In a driving impairment case, quantification is required to determine whether the blood concentration exceeded a statutory limit. In a workplace positive, the confirmation concentration may be relevant when the donor claims a legitimate medical prescription: a confirmed morphine concentration of 5,000 ng/mL is more consistent with opiate abuse than with codeine phosphate taken at the labelled dose.